Академический Документы
Профессиональный Документы
Культура Документы
March 9, 2012
Aurobindo Pharma
Performance Highlights
Y/E March (` cr) Net sales Other income Operating profit Interest Adj. Net profit 3QFY2012 1262 28 168 172 (29) 2QFY2012 1075 6 115 21 (80) % chg (qoq) 17.3 364.7 46.9 730.2 3QFY2011 1072 126 186 7 194 % chg (yoy) 17.7 (78.0) (9.7) 2228.6 -
BUY
CMP Target Price
Investment Period
Stock Info Sector Market Cap (` cr) Beta 52 Week High / Low Avg. Daily Volume Face Value (`) BSE Sensex Nifty Reuters Code Bloomberg Code Pharmaceutical 3,351 1.0 209/80 239,059 1 17,503 5,334 ARBN.BO ARBP@IN
`112 `166
12 months
For 3QFY2012, Aurobindo Pharmaceuticals (APL) posted above expectations, in the area of operating profits. The companys top line was just in line with our estimates. The highlight of the quarter was, better than expected OPMs. The OPM came in at 13.3% V/s expectations of 12.1%. However, including the forex losses and redemptions the company reported losses. We maintain our Buy view on the stock. Above expectations results: Net sales grew modestly by 17.7% yoy to `1,262cr, mainly on the robust growth in the exports and domestic. ARV, both formulations and API was the main growth driver of the company which grew by 47.8% and 106.1% respectively. Other key geographies, like US and Europe & ROW formulations grew by (-0.9)% and 17.4% growth respectively. Gross margin came in at 45.1% (46.7%), impacted by higher raw-material costs, thus impacting the OPMs which came in at 13.3% V/s expectations of 12.1%. However, including the forex losses and redemptions the company reported losses. Outlook and valuation: Commencement of operations at the Hyderabad SEZ and incremental contribution from the Pfizer deal would boost APLs earnings with better growth visibility going forward. We estimate net sales to log a 12.7% CAGR to `5,243cr over FY201113E on the back of supply agreements and the US and ARV formulation contracts. Even after factoring in lower profitability going forward, the stock trades at attractive valuations. Hence, we maintain a Buy with a revised price target of `166. Key financials (Consolidated)
Y/E March (` cr) Net sales % chg Net profit % chg Recurring profit % chg EPS (`) Recurring EPS EBITDA margin (%) P/E (x) RoE (%) RoCE (%) P/BV (x) EV/Sales (x) EV/EBITDA (x)
Source: Company, Angel Research
Shareholding Pattern (%) Promoters MF / Banks / Indian Fls FII / NRIs / OCBs Indian Public / Others 54.7 16.3 14.5 14.5
3m 6.2 26.3
1yr
3yr
FY2009 2,935 20.8 100 (58.0) 169 26.3 3.7 6.3 12.7 17.8 25.5 7.3 2.4 1.8 13.9
FY2010 3,370 14.8 563 463 304 79.4 20.2 10.9 18.3 10.3 29.6 12.1 1.7 1.5 8.3
FY2011 4,126 22.4 563 (0.0) 332 9.2 19.3 11.4 17.1 9.8 24.6 11.7 1.3 1.3 7.7
FY2012E 4,519 9.5 462 (18.0) 343 3.5 15.9 11.8 14.8 9.5 17.1 9.4 1.1 1.1 7.3
FY2013E 5,243 16.0 480 3.9 401 16.8 16.5 13.8 14.6 8.1 15.1 10.2 0.9 0.9 6.5
3QFY2012 1,262 28 1,289 556 44.1 168 13.3 172 55 (31) (2) (29) (29) 116 4.0
2QFY2012 1,075 6 1,081 476 44.3 115 10.7 21 46 54 (52) 105 186 (80) (80) -
% chg (qoq) 19.5 (17.3) 19.3 21.7 66.8 730.2 19.5 (157.7) (127.2) -
3QFY2011 1,072 126 1,198 501 46.7 191 17.9 7 43 267 78 189 (5) 194 189 6.5
9MFY2012 3,380 71 3,451 1559 45.3 470 13.9 389 147 5 (141) 145 (327) (232)
9MFY2011 2,769 477 3,247 3247 47.2 516 18.7 44 124 826 190 636 31 438 444 15.2
(7.7) (80.1)
(38.6)
88 3.0
Actuals
Estimate
Variation %
1295 28 156 15 99
Revenue up at 17.7% yoy, in line with expectations: Net sales grew modestly by 17.7% yoy to `1,262cr. ARV, both formulations and API was the main growth driver of the company which grew by 47.8% and 106.1% respectively. Other key geographies, like US and Europe & ROW formulations grew by (-0.9)% and 17.4% growth respectively. Overall formulations and the API segment, on the other hand, grew by 14.7% yoy. The US formulation segment remained flat at `325cr (`328cr). The ARV formulation segment reported modest growth of 47.8% yoy growth to `209cr (`141cr). As a result, contribution from the formulations segment to net sales decreased to 57% in 3QFY2012 from 59% in 3QFY2011. The API segment posted growth of 20.3% yoy to `548cr (`456cr), driven by SSP, which grew by 15.1% yoy. As of December 2011, the company now has 144 approved ANDAs and 29 tentative approvals, with the cumulative filings to 233.
March 9, 2012
% chg (qoq) 24.8 14.9 17.4 55.4 11.9 4.7 13.7 16.5
% chg (yoy) 14.7 (0.9) 17.4 47.8 20.3 15.1 (13.2) 106.1
OPM dips by 410bp for the quarter: Gross margin came in at 45.1% (46.7%), impacted by higher raw-material costs, thus impacting the OPMs which came in at 13.3% V/s 17.4% in 3QFY2011. However, on the positive side the OPMs were higher than the expectations of 12.1%. The margins expanded, on back of lower than expected growth in other expenditure. Net profit higher than estimates: For the quarter, APL reported losses on account of Adjusted net loss came in at `29cr (`194cr) for the quarter.
Management takeaways
Management has guided for 25 new launches in US out of which 12 will be done through Unit VII and 11 from Unit III post USFDA resolution. Expect launch of 1 OC product in FY2013. No clarity on timelines with the resolution of the USFDA issue w.r.t. the Unit III and VI. Inspection is scheduled in March2012 for Unit III and in July2012 for Unit VI. As of December, 2011, gross debt on books around `3,300cr, with cash of `125cr. Tax Rate is guided at 18-20% of PBT.
Recommendation rationale
Supply agreements to drive growth: On the global filings front (ANDAs and dossiers), APL has increased its filing dramatically from 313 in FY2008 to 1,171 in FY2010, as it proposes to scale up from SSP and Cephs to NPNC products. Further, the companys transformation from being a pure API supplier to becoming a formidable formulations player has increased APLs cost efficiencies, as 90% of its formulation is now backward integrated. Thus, to leverage on its cost efficiency and strong product filings, APL entered into long-term supply agreements with Pfizer (March 2009) and AstraZeneca (September 2010), which provide significant revenue visibility going ahead. APL is also in discussion with other MNCs for more supply agreements.
March 9, 2012
US and ARV formulation segments The key drivers for base business: APLs business, excluding the supply agreements, would primarily be driven by the US and ARV segments on the formulation front. APL has been an aggressive filer in the US market, with 209 ANDAs filed and 134 approvals received until FY2011. Amongst peers, APL is the third-largest ANDA filer. The company has aggressively filed ANDAs in the last three years and is now geared to reap benefits, even though most of the filings are for highly competitive products. APL expects to file 1520 ANDAs every year going forward. Going ahead, during the next three years in the US with US$70bn going off-patent, one of the highest in history, we believe APL is well placed to tap this opportunity. We expect the base business (ex-Pfizer) to post a 36.0% CAGR over FY201012 and contribute US$268mn by FY2012, with revenue per product increasing to US$2.6mn from US$2.3mn in FY2010, as the company moves towards the high revenue-generating NPNC and injectable (SSP and Cephs) products. APL is one of the largest generic suppliers under ARV contracts, with a 35% market share. The company enjoys high market share as it is fully integrated in all its products apart from having a larger product basket. Overall, we expect the ARV segment to post a 21.4% CAGR over FY2010-12E to `730cr, with PEPFAR allocation for generic ARVs expected to increase.
March 9, 2012
86.3 48.2 24.4 10.7 13.7 62.0 39.0 13.5 18.4 47.4 -
Accumulate 1,688
Source: Company, Angel Research; Note: *December year ending; Based on CY2012 estimates
March 9, 2012
Apr-05 Jul-05 Oct-05 Jan-06 Apr-06 Jul-06 Oct-06 Jan-07 Apr-07 Jul-07 Oct-07 Jan-08 Apr-08 Jul-08 Oct-08 Jan-09 Apr-09 Jul-09 Oct-09 Jan-10 Apr-10 Jul-10 Oct-10 Jan-11 Apr-11 Jul-11 Oct-11 Jan-12
5x 10x 15x 20x
FY2013E EV/EBITDA (x) 4.6 6.0 16.9 13.3 15.2 12.1 5.4 13.2 6.5 7.3 12.7 6.3 5.7 16.5 5.6 8.1 22.6 15.6 18.1 17.6 5.0 21.7 8.0 10.6 16.9 6.6 8.1 20.9 0.7 0.9 2.5 2.5 3.2 3.1 1.0 5.4 0.9 1.6 2.5 1.3 1.4 6.0
FY11-13E 34.8 9.9 5.6 11.7 16.9 22.7 0.6 37.7 15.6 25.4 23.9 13.7 21.8 23.5
FY2013E RoE (%) 38.0 15.0 15.4 29.5 17.0 24.9 8.5 30.7 16.9 27.8 28.6 15.8 30.0 22.5 26.6 10.2 15.1 17.2 15.5 21.8 7.3 41.0 14.2 25.9 24.8 8.9 27.7 22.6
March 9, 2012
March 9, 2012
March 9, 2012
Key ratios
Y/E March Valuation Ratio (x) P/E (on FDEPS) P/CEPS P/BV Dividend yield (%) EV/Sales EV/EBITDA EV / Total Assets Per Share Data (`) EPS (Basic) EPS (fully diluted) Cash EPS DPS Book Value Dupont Analysis EBIT margin Tax retention ratio Asset turnover (x) ROIC (Post-tax) Cost of Debt (Post Tax) Leverage (x) Operating ROE Returns (%) ROCE (Pre-tax) Angel ROIC (Pre-tax) ROE Turnover ratios (x) Asset Turnover (Gross Block) Inventory / Sales (days) Receivables (days) Payables (days) WC cycle (ex-cash) (days) Solvency ratios (x) Net debt to equity Net debt to EBITDA Interest Coverage (EBIT / Int.) 1.4 4.8 3.5 1.8 5.9 2.6 1.1 3.4 6.4 0.9 3.2 8.5 0.5 2.0 11.1 0.4 1.6 13.6 1.6 108 97 78 174 1.8 99 92 70 169 1.7 101 94 74 169 1.7 107 92 67 168 1.5 112 99 70 177 1.5 103 94 70 162 7.8 10.3 23.7 7.3 9 25.5 12.1 15 29.6 11.7 14 24.6 12.0 14 20.7 13.8 16 19.0 9.9 81.6 0.9 7.5 2.8 1.6 14.7 8.4 82.4 1.0 6.7 3.6 1.6 11.7 13.9 74.6 0.9 9.8 2.4 1.5 20.6 12.9 71.4 1.0 9.2 2.0 1.0 16.6 13.3 77.0 1.0 9.9 2.0 0.7 15.7 13.9 76.9 1.1 11.3 2.3 0.5 15.5 8.9 8.9 12.6 0.7 41.8 3.7 11.2 8.5 0.9 46.2 20.2 16.3 25.6 1.0 65.7 19.3 18.1 25.2 1.1 84.0 19.5 19.5 26.6 1.2 104.8 21.8 21.8 29.8 1.3 125.1 12.6 8.9 2.7 0.6 1.9 13.6 1.5 17.8 13.2 2.4 0.8 1.8 13.9 1.4 10.3 4.4 1.7 0.9 1.5 8.4 1.3 9.8 4.4 1.3 1.0 1.3 7.8 1.1 9.5 4.9 1.1 0.9 1.1 7.3 1.0 8.1 4.6 1.0 0.9 1.0 6.5 0.9 FY2008 FY2009 FY2010 FY2011E FY2012E FY2013E
March 9, 2012
E-mail: research@angelbroking.com
Website: www.angelbroking.com
DISCLAIMER This document is solely for the personal information of the recipient, and must not be singularly used as the basis of any investment decision. Nothing in this document should be construed as investment or financial advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in the securities of the companies referred to in this document (including the merits and risks involved), and should consult their own advisors to determine the merits and risks of such an investment. Angel Broking Limited, its affiliates, directors, its proprietary trading and investment businesses may, from time to time, make investment decisions that are inconsistent with or contradictory to the recommendations expressed herein. The views contained in this document are those of the analyst, and the company may or may not subscribe to all the views expressed within. Reports based on technical and derivative analysis center on studying charts of a stock's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamentals. The information in this document has been printed on the basis of publicly available information, internal data and other reliable sources believed to be true, but we do not represent that it is accurate or complete and it should not be relied on as such, as this document is for general guidance only. Angel Broking Limited or any of its affiliates/ group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Angel Broking Limited has not independently verified all the information contained within this document. Accordingly, we cannot testify, nor make any representation or warranty, express or implied, to the accuracy, contents or data contained within this document. While Angel Broking Limited endeavours to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. This document is being supplied to you solely for your information, and its contents, information or data may not be reproduced, redistributed or passed on, directly or indirectly. Angel Broking Limited and its affiliates may seek to provide or have engaged in providing corporate finance, investment banking or other advisory services in a merger or specific transaction to the companies referred to in this report, as on the date of this report or in the past. Neither Angel Broking Limited, nor its directors, employees or affiliates shall be liable for any loss or damage that may arise from or in connection with the use of this information. Note: Please refer to the important `Stock Holding Disclosure' report on the Angel website (Research Section). Also, please refer to the latest update on respective stocks for the disclosure status in respect of those stocks. Angel Broking Limited and its affiliates may have investment positions in the stocks recommended in this report.
Disclosure of Interest Statement 1. Analyst ownership of the stock 2. Angel and its Group companies ownership of the stock 3. Angel and its Group companies' Directors ownership of the stock 4. Broking relationship with company covered
Aurobindo Pharma No No No No
Note: We have not considered any Exposure below ` 1 lakh for Angel, its Group companies and Directors.
Ratings (Returns):
March 9, 2012
10